本文選題：胸腔鏡　切入點：胸腺擴大切除術　出處：《中國內鏡雜志》2017年04期

【摘要】：目的評估胸腔鏡胸腺擴大切除術治療重癥肌無力(MG)的療效,并分析影響手術療效的因素。方法回顧性分析2011年1月-2016年5月該院收治的行胸腔鏡胸腺擴大切除術的183例MG患者的臨床資料,采用美國重癥肌無力聯(lián)盟(MGFA)標準評價手術療效。采用單因素分析和Cox比例風險模型分析影響手術療效的因素。結果 183例患者中,173例患者完成隨訪,失訪10例,隨訪率94.5%。其中完全穩(wěn)定緩解(CSR)率為66.5%、藥物緩解(PR)率為7.5%、微小癥狀表現(xiàn)(MM)率為1.2%、改善(I)率為1.2%、無變化(U)率為11.6%、復發(fā)(E)率為4.6%、死亡(D)率為1.7%。進一步分析顯示年齡(RR=1.53,P=0.031)、病理類型(RR=5.84,P=0.022)、MGFA分型(RR=3.72,P=0.028)是影響手術療效的因素。結論胸腔鏡擴大切除術治療MG患者療效顯著,且年齡、病理類型及MGFA分型是影響手術療效的主要因素。
[Abstract]:Objective to evaluate the efficacy of thoracoscopic extended thymectomy in the treatment of myasthenia gravis (MG). Methods the clinical data of 183 patients with MG treated by thoracoscopic thymectomy from January 2011 to May 2016 were analyzed retrospectively. The surgical outcome was evaluated by American Myasthenia Gravis Alliance (MGFAA) standard. Univariate analysis and Cox proportional risk model were used to analyze the factors affecting the outcome of the operation. Results 173 of 183 patients were followed up, 10 of them were not visited. The follow-up rate was 94.5.The total stable remission rate was 66.5, the drug remission PRR rate was 7.5, the minor symptom symptom MMR rate was 1.2, the improvement I) rate was 1.2, the no change Ur) rate was 11.6, the recurrence rate was 4.6, the death Drate was 1.7.The further analysis showed that the age was 1.53%, and the disease was 1.03%. RRN 5.84 P0. 022 MGFA typing and RRGFA 3.72 P0. 028) are the factors that influence the outcome of the operation. Conclusion the effect of thoracoscopic extended resection on MG patients is significant. Age, pathological type and MGFA classification were the main factors affecting the outcome of operation.
【作者單位】： 河南省胸科醫(yī)院胸外一科;河南省胸科醫(yī)院病理科;
【分類號】：R655.7;R746.1
，

本文編號：1677452